ArriVent BioPharma Files Q1 2025 10-Q
Ticker: AVBP · Form: 10-Q · Filed: May 12, 2025 · CIK: 1868279
| Field | Detail |
|---|---|
| Company | Arrivent Biopharma, INC. (AVBP) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
ArriVent BioPharma's Q1 2025 10-Q is in. Check financials.
AI Summary
ArriVent BioPharma, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations. Key financial data points include common stock information and changes in retained earnings and additional paid-in capital as of March 31, 2025, compared to December 31, 2024.
Why It Matters
This filing provides investors with an update on ArriVent BioPharma's financial health and operational status for the first quarter of 2025.
Risk Assessment
Risk Level: low — This is a standard quarterly financial filing with no immediate red flags or significant new disclosures.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Marks the end of the financial quarter being reported.)
- 2025-05-12 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- ArriVent BioPharma, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250512 (date) — Filing date
- 0001868279 (company) — Central Index Key for ArriVent BioPharma, Inc.
FAQ
What is the total revenue for ArriVent BioPharma for the quarter ending March 31, 2025?
The provided text is an excerpt from the header and does not contain detailed financial statements, so total revenue cannot be determined from this snippet.
What were the net earnings or losses for ArriVent BioPharma in Q1 2025?
This specific excerpt does not include the income statement, making it impossible to determine net earnings or losses.
Are there any significant changes in ArriVent BioPharma's cash position reported in this 10-Q?
The provided text focuses on the filing details and equity components, not the cash flow statement, so changes in cash position are not detailed here.
What is the current status of ArriVent BioPharma's common stock as of March 31, 2025?
The filing indicates common stock activity and balances for the period ending March 31, 2025, with specific details available within the full report.
Does this filing mention any new clinical trial updates or regulatory milestones for ArriVent BioPharma?
The provided header information does not contain details on clinical trials or regulatory updates; these would be found in the business or risk factors sections of the full 10-Q.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding ArriVent BioPharma, Inc. (AVBP).